Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

Mina Fazel; Romain Varnier; Hélène Vanacker; Nicolas Penel; Sarah Watson; Benjamin Verret; Thibaud Valentin; Emmanuelle Bompas; Waïsse Waïssi; Alexandra Meurgey; Françoise Ducimetière; Jean Yves Blay; Armelle Dufresne; Mehdi Brahmi

doi:10.1002/cncr.70052

Back

Shared by

Jean Yves Blay

Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

Article 2025 en

Authors

MF
Mina Fazel
RV
Romain Varnier
HV
Hélène Vanacker

Abstract

1 min read

Despite a short median PFS, certain histological subtypes, including ASPS, chordomas, SMARCA4-deficient tumors, gastro-intestinal stromal tumor, and NF1 mutations, showed strong activity signals, indicating long-term responses in some patients.

Related publications

Article2024

89P IMmunotherapy response associated clinical and biological PREdictive factors in advanced SARComas: A retrospective multicenter study

Mina Fazel, Romain Varnier, Jean Yves Blay, Mehdi Brahmi

Article2021

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

Jean Yves Blay, Nicolas Penel, Isabelle Laure Ray-Coquard, Sophie Cousin, François Bertucci, Emmanuelle Bompas, Jean‐Christophe Eymard, Esma Saâda-Bouzid, P Soulié, Pascaline Boudou‐Rouquette, Armelle Dufresne, Axel Le Cesne, Olivier Mir, Laëtitia Gambotti, Frédéric Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Sylvie Chevret, Christophe Massard

Article2014

Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.

Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Richard A Scolyer, Richard Kefford, Georgina V. Long, Helen Rizos

Article2018

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, José Alejandro Pérez Fidalgo, Santiago González Santiago, Montserrat Muñoz, Raquel Andrés, Cristina Cruz Zambrano, Sebastian Moran Salama, Sara López‐Tarruella, Vanesa Garcı́a, Sònia Servitja, Mireia Melé, Sonia Alonso Soler, Bárbara Adamo, M.J. Escudero, N Martin, Susana Bezares, Rosalía Caballero, Manel Esteller, Federico Rojo

Editorial Material2025

Treatment Decision Making in Unresectable HCC: Importance to Understand the Different Response Patterns Between IO Plus Anti-VEGF and IO Plus IO Regimens in Hepatocellular Carcinoma

Masatoshi Kudo

Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

Abstract

Discussion(0)

Related publications

89P IMmunotherapy response associated clinical and biological PREdictive factors in advanced SARComas: A retrospective multicenter study

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

Correlation between pre-existing MEK1<sup>P124</sup> mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.

A phase II clinical trial to analyze olaparib response in patients with <i>BRCA1</i> and/or <i>BRCA</i>2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

Treatment Decision Making in Unresectable HCC: Importance to Understand the Different Response Patterns Between IO Plus Anti-VEGF and IO Plus IO Regimens in Hepatocellular Carcinoma